Incyte (NASDAQ:INCY) Issues Quarterly Earnings Results

Incyte (NASDAQ:INCY) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported $3.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.20 by $0.89, FiscalAI reports. Incyte had a net margin of 26.71% and a return on equity of 26.66%. The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same quarter last year, the firm earned $1.57 EPS. The company’s revenue was up 37.7% on a year-over-year basis.

Here are the key takeaways from Incyte’s conference call:

• Broad-based commercial growth: Second-quarter net product sales rose 40% year over year, or 17% excluding a $246 million one-time CMS-related benefit. Jakafi, OPZELURA, Niktimvo, MONJUVI, and ZYNYZ all posted higher sales, supporting management’s strategy to diversify beyond Jakafi.
• Guidance was raised: Full-year 2026 total net sales guidance increased to $5.13 billion-$5.26 billion, with OPZELURA guidance raised to $1.05 billion-$1.10 billion and hematology/oncology guidance increased to $860 million-$890 million.
• Jakafi XR launch is progressing: The company is on track for 50%-70% formulary coverage by year-end, while physician adoption is expected to accelerate through 2027. Jakafi XR sales are projected at approximately $40 million-$50 million in 2026.
• Pipeline and regulatory catalysts remain substantial: Incyte expects multiple approvals, launches, and data readouts in the second half of 2026, including OPZELURA in European atopic dermatitis, povorcitinib studies, and oncology updates at ESMO for its G12D, TGF-beta/PD-1, and CDK2 programs.
• One clinical program was discontinued: Incyte halted development of INCA058, its lead JAK2 V617F-targeted asset, citing an insufficiently differentiated efficacy, safety, and pharmacokinetic profile. The company plans to prioritize next-generation JAK2 programs instead.

Incyte Stock Down 1.7%

INCY traded down $2.17 during trading on Wednesday, reaching $127.76. The stock had a trading volume of 262,568 shares, compared to its average volume of 1,771,604. The stock’s 50 day moving average is $107.99 and its two-hundred day moving average is $101.86. The company has a current ratio of 3.68, a quick ratio of 3.60 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $25.52 billion, a price-to-earnings ratio of 18.14, a P/E/G ratio of 1.03 and a beta of 0.76. Incyte has a one year low of $73.81 and a one year high of $132.60.

Incyte News Summary

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q2 results exceeded expectations: Revenue rose 38% year over year to $1.67 billion, while adjusted EPS of $3.09 surpassed the $2.20 consensus estimate. Total net sales increased 40% to $1.49 billion. Incyte quarterly earnings report
• Positive Sentiment: 2026 guidance was raised: Incyte now expects total net sales of $5.13 billion to $5.26 billion, up from its prior $4.77 billion to $4.94 billion forecast. Opzelura guidance increased to $1.05 billion-$1.10 billion following a CMS settlement.
• Positive Sentiment: Broad portfolio growth strengthened the outlook: Jakafi sales rose 7% to $817 million, Opzelura sales surged 173% to $450 million, and the Hematology and Oncology portfolio grew 69% to $222 million. The CMS agreement includes an estimated $300 million-$310 million 2026 Opzelura benefit, including a $246 million one-time non-cash contribution. Ten clinical readouts, including four registrational trials, are expected in the second half of 2026. Incyte Q2 outlook analysis
• Neutral Sentiment: Analyst views are mixed: HC Wainwright raised its Buy price target from $140 to $150, while UBS reiterated Hold with a $113 target, suggesting the recent rally may have limited near-term upside according to UBS.
• Negative Sentiment: Valuation and execution risks remain: Several analysts’ targets remain below the current market level, and Incyte discontinued an early-stage JAK inhibitor program to focus on next-generation candidates. Reported insider activity also showed selling without purchases over the past six months, though such transactions may not reflect management’s current business outlook.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Truist Financial upped their price objective on shares of Incyte from $103.00 to $105.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Guggenheim reissued a “buy” rating and issued a $150.00 target price on shares of Incyte in a research note on Wednesday. Weiss Ratings restated a “buy (b-)” rating on shares of Incyte in a report on Monday, June 29th. UBS Group upped their price target on Incyte from $103.00 to $113.00 and gave the company a “neutral” rating in a research report on Friday, June 26th. Finally, Barclays increased their price objective on Incyte from $134.00 to $139.00 and gave the stock an “overweight” rating in a report on Wednesday. Eight research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Incyte currently has a consensus rating of “Hold” and a consensus target price of $116.50.

Institutional Trading of Incyte

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. grew its holdings in shares of Incyte by 13.2% during the fourth quarter. Invesco Ltd. now owns 3,473,781 shares of the biopharmaceutical company’s stock valued at $343,105,000 after buying an additional 405,611 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Incyte by 13.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,103,946 shares of the biopharmaceutical company’s stock worth $263,246,000 after acquiring an additional 373,298 shares during the last quarter. Morgan Stanley raised its holdings in Incyte by 0.9% in the 4th quarter. Morgan Stanley now owns 2,663,823 shares of the biopharmaceutical company’s stock worth $263,106,000 after acquiring an additional 23,087 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in Incyte by 31.0% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 2,284,317 shares of the biopharmaceutical company’s stock valued at $225,622,000 after acquiring an additional 540,523 shares in the last quarter. Finally, Man Group plc lifted its position in Incyte by 20.0% in the 3rd quarter. Man Group plc now owns 1,933,547 shares of the biopharmaceutical company’s stock valued at $163,984,000 after acquiring an additional 322,877 shares in the last quarter. 96.97% of the stock is owned by hedge funds and other institutional investors.

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.